Figure 2.

Different immune therapies illicit distinct transcriptomic profiles. RNA isolated from bulk tumor at D4 was analyzed with NanoString pan-cancer immune kit and sequenced by Affymetrix. a. NanoString undirected global significance scores from each treatment group representing variation in gene expression across gene sets vs isotype treated tumors. b. Directed NanoString global significance scores representing a net positive or negative direction to the overall variation in gene expression in a geneset. Gene sets cluster into that differentiate combination immunotherapies are labeled 1–3: Cluster 1 includes gene sets with positive directed global significance scores in both combinations. Cluster 2 includes gene sets with negative scores in both combinations. Cluster 3 includes gene sets with positive scores in α-CTLA-4/α-PD-1 and negative in α-PD-1/α-OX40 treated tumors c. Leading edge metagene analysis from Affymetrix representing gene sets represented by the metagenes associated with combination therapy vs isotype treated tumors. d. Summary flow cytometry analysis of tumor infiltrating CD8 T cell memory subsets